PRI-724 is under clinical development by PRISM Pharma and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect PRI-724’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 30 Jul 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their PRI-724 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

PRI-724 overview

PRI-724 (OP-724) is under development for the treatment of HCV or HBV-induced liver cirrhosis, leukemia such as acute myeloid leukemia (AML), neuroendocrine tumors, chronic myeloid leukemia (CML), metastatic colorectal cancer, retinal fibrosis, primary biliary cholangitis, idiopathic pulmonary fibrosis, gastrointestinal tumors such as small bowel carcinoma and gastrointestinal neuroendocrine tumors, desmoid tumors, anaplastic thyroid cancer (ATC), endometrial cancer, melanoma, myelodysplastic syndrome, colorectal cancer (CRC), hepatocellular carcinoma (HCC), pancreatic cancer, prostate cancer and ovarian cancer. The drug candidate is administered through intravenous and oral route. PRI-724 is a new chemical entity. It acts by targeting CBP/beta-catenin complex formation, and modulates the beta-catenin dependent pathway of Wnt signaling to provide a selective cell anti-proliferative effect. PRI-724 is generated by using the PRISM’s proprietary optimization technology. It was also under development for the treatment of choroidal neovascularization, proliferative vitreoretinopathy (PVR), hematological cancer, colorectal cancer (third line therapy), advanced or metastatic pancreatic adenocarcinoma and metastatic colorectal cancer (first line therapy).

PRISM Pharma overview

Prism Pharma Co Ltd (Prism Pharma) is a biopharmaceutical company. The Company researches and develops therapeutic compounds for protein interactions. It is headquartered in Yokohama,Japan.

Quick View PRI-724 LOA Data

Report Segments
  • Innovator
Drug Name
  • PRI-724
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Gastrointestinal
  • Non Malignant Disorders
  • Oncology
  • Ophthalmology
  • Respiratory
Key Developers
  • Sponsor Company: PRISM Pharma
  • Originator: PRISM Pharma
Highest Development Stage
  • Phase II


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.